BACKGROUND: The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia (ALL). METHODS: This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome-negative ALL who were receiving frontline chemotherapy. Three hundred thirty patients (77%) were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone-based regimens, and 98 (23%) were treated with the augmented Berlin-Frankfurt-Munster regimen. RESULTS: The median age was 40 years (range, 13-86 years). One hundred eighty-six patients (43%) had diploid cytogenetics, 32 (7%) had complex cytogenetics (defined as ≥ 5 chromosomal abnormalities), 27 (6%) had low hypodiploidy/near-triploidy (Ho-Tr), 24 (6%) had high hyperdiploidy, and 24 (6%) had a mixed-lineage leukemia (MLL) rearrangement. Patients with an MLL rearrangement, Ho-Tr, or a complex karyotype had significantly worse relapse-free survival (RFS) and overall survival (OS) than the diploid group. According to a multivariate analysis including all the baseline characteristics and MRD status, Ho-Tr and a complex karyotype were independent predictive factors for worse RFS and OS. Furthermore, survival among all cytogenetic groups was similar, regardless of the treatment received. CONCLUSIONS: A complex karyotype and Ho-Tr are adverse prognostic factors for adults with ALL independently of the MRD status. These findings suggest that pretreatment cytogenetics remain a valuable prognostic tool in this population. Cancer 2017;123:459-467.
BACKGROUND: The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia (ALL). METHODS: This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome-negative ALL who were receiving frontline chemotherapy. Three hundred thirty patients (77%) were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone-based regimens, and 98 (23%) were treated with the augmented Berlin-Frankfurt-Munster regimen. RESULTS: The median age was 40 years (range, 13-86 years). One hundred eighty-six patients (43%) had diploid cytogenetics, 32 (7%) had complex cytogenetics (defined as ≥ 5 chromosomal abnormalities), 27 (6%) had low hypodiploidy/near-triploidy (Ho-Tr), 24 (6%) had high hyperdiploidy, and 24 (6%) had a mixed-lineage leukemia (MLL) rearrangement. Patients with an MLL rearrangement, Ho-Tr, or a complex karyotype had significantly worse relapse-free survival (RFS) and overall survival (OS) than the diploid group. According to a multivariate analysis including all the baseline characteristics and MRD status, Ho-Tr and a complex karyotype were independent predictive factors for worse RFS and OS. Furthermore, survival among all cytogenetic groups was similar, regardless of the treatment received. CONCLUSIONS: A complex karyotype and Ho-Tr are adverse prognostic factors for adults with ALL independently of the MRD status. These findings suggest that pretreatment cytogenetics remain a valuable prognostic tool in this population. Cancer 2017;123:459-467.
Authors: E Coustan-Smith; J Sancho; M L Hancock; J M Boyett; F G Behm; S C Raimondi; J T Sandlund; G K Rivera; J E Rubnitz; R C Ribeiro; C H Pui; D Campana Journal: Blood Date: 2000-10-15 Impact factor: 22.113
Authors: H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Forida Y Mortuza; Mary Papaioannou; Ilidia M Moreira; Luke A Coyle; Paula Gameiro; Domenica Gandini; H Grant Prentice; Anthony Goldstone; A Victor Hoffbrand; Letizia Foroni Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien Journal: Lancet Oncol Date: 2012-02-21 Impact factor: 41.316
Authors: H Cavé; J van der Werff ten Bosch; S Suciu; C Guidal; C Waterkeyn; J Otten; M Bakkus; K Thielemans; B Grandchamp; E Vilmer Journal: N Engl J Med Date: 1998-08-27 Impact factor: 91.245
Authors: Vinod Pullarkat; Marilyn L Slovak; Kenneth J Kopecky; Stephen J Forman; Frederick R Appelbaum Journal: Blood Date: 2007-12-21 Impact factor: 22.113
Authors: Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone Journal: Blood Date: 2013-11-25 Impact factor: 22.113
Authors: Nicholas J Short; Hagop M Kantarjian; Koji Sasaki; Farhad Ravandi; Heidi Ko; C Cameron Yin; Guillermo Garcia-Manero; Jorge E Cortes; Rebecca Garris; Susan M O'Brien; Keyur Patel; Maria Khouri; Deborah Thomas; Nitin Jain; Tapan M Kadia; Naval G Daver; Christopher B Benton; Ghayas C Issa; Marina Konopleva; Elias Jabbour Journal: Am J Hematol Date: 2017-02-03 Impact factor: 10.047
Authors: Guillaume Richard-Carpentier; Hagop M Kantarjian; Guilin Tang; C Cameron Yin; Joseph D Khoury; Ghayas C Issa; Fadi Haddad; Nitin Jain; Farhad Ravandi; Nicholas J Short; Courtney D DiNardo; Koichi Takahashi; Marina Y Konopleva; Naval G Daver; Tapan Kadia; Guillermo Garcia-Manero; Rebecca Garris; Susan O'Brien; Elias Jabbour Journal: Blood Adv Date: 2021-12-14